Cytosorbents outlines cash flow breakeven path for second half of 2026 amid international sales growth [Seeking Alpha]
Cytosorbents Corporation (CTSO)
Last cytosorbents corporation earnings: 11/5 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cytosorbents.com
Company Research
Source: Seeking Alpha
CEO Phillip Chan described 2025 as “a transitional year for the company, during which we made measurable progress across four key priorities,” including driving sales growth outside of Germany, advancing DrugSorb-ATR through the FDA Fresh Stock Ideas, Every Day Quick Insights Cytosorbents cited leadership changes, organizational realignment, and operational restructuring in Germany, reporting early signs of improvement and affirmed that restructuring is now in execution stage. The initial FDA De Novo submission was denied, but management highlighted no safety concerns and ongoing discussions with the FDA to resolve remaining open items, emphasizing a cautious and conservative approach to avoid further denials. Management now guides for breakeven in the second half of 2026, citing ongoing cost reductions and normalizing working capital, shifting from earlier guidance targeting Q1 2026. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
CTSO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTSO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTSO alerts
High impacting Cytosorbents Corporation news events
Weekly update
A roundup of the hottest topics
CTSO
News
- Cytosorbents (CTSO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
- CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... [Yahoo! Finance]Yahoo! Finance
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsPR Newswire
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026PR Newswire
CTSO
Earnings
- 3/25/26 - Miss
CTSO
Sec Filings
- 3/25/26 - Form 8-K
- 2/13/26 - Form SCHEDULE
- CTSO's page on the SEC website